Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Role of cfDNA and ctDNA to improve the risk stratification and the disease follow-up in patients with endometrial cancer, towards the clinical application

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Vilar, Ana
  • Cueva, Juan|||0000-0003-1389-4595
  • Arias, Efigenia
  • Sampayo, Victoria
  • Diaz, Eva
  • Oltra, Sara S.
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Cortegoso, Alexandra
  • Curiel, Teresa
  • Abalo, Alicia
  • Pamies Serrano, Mónica
  • Domingo, Santiago
  • Padilla-Iserte, Pablo
  • Arnaez de la Cruz, Marta
  • Hernández Gutierrez, Alicia|||0000-0002-2494-3041
  • García-Pineda, Virginia
  • Ruiz-Bañobre, Juan
  • López, Rafael
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
There has been a rise in endometrial cancer (EC) incidence leading to increased mortality. To counter this trend, improving the stratification of post-surgery recurrence risk and anticipating disease relapse and treatment resistance is essential. Liquid biopsy analyses offer a promising tool for these clinical challenges, though the best strategy for applying them in EC must be defined. This study was designed to determine the value of cfDNA/ctDNA monitoring in improving the clinical management of patients with localized and recurrent disease. Plasma samples and uterine aspirates (UA) from 198 EC patients were collected at surgery and over time. The genetic landscape of UAs was characterized using targeted sequencing. Total cfDNA was analyzed for ctDNA presence based on the UA mutational profile. High cfDNA levels and detectable ctDNA at baseline correlated with poor prognosis for DFS (p-value < 0.0001; HR = 9.25) and DSS (p-value < 0.0001; HR = 11.20). This remained clinically significant when stratifying tumors by histopathological risk factors. Of note, cfDNA/ctDNA analyses discriminated patients with early post-surgery relapse and the ctDNA kinetics served to identify patients undergoing relapse before any clinical evidence emerged. This is the most comprehensive study on cfDNA/ctDNA characterization in EC, demonstrating its value in improving risk stratification and anticipating disease relapse in patients with localized disease. CtDNA kinetics assessment complements current strategies to monitor the disease evolution and the treatment response. Therefore, implementing cfDNA/ctDNA monitoring in clinical routines offers a unique opportunity to improve EC management. The study demonstrates that high levels of cfDNA and detectable ctDNA at baseline are strong indicators of poor prognosis. This enables more accurate risk stratification beyond traditional histopathological factors, allowing clinicians to identify high-risk patients who may benefit from more aggressive treatment and closer monitoring. Moreover, longitudinal analysis of cfDNA/ctDNA can detect disease recurrence months before clinical symptoms or imaging evidence appear. This early warning system offers a significant advantage in clinical practice, providing a window of opportunity for early intervention and potentially improving patient outcomes. The online version contains supplementary material available at 10.1186/s13046-024-03158-w.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Structural and functional insights into GSDMB isoforms complex roles in pathogenesis

  • Colomo, Sara
  • Ros-Pardo, David
  • Oltra, Sara S.
  • Gómez-Puertas, Paulino
  • Sarrió, David
  • Moreno-Bueno, Gema
ABSTRACT SHADS: Gasdermins (GSDMs) have garnered significant scientific interest due to their protective and detrimental roles in innate immunity, host defense, inflammation, and cancer alongside with other pathologies. While GSDMs are mostly recognized as key effectors of a lytic type of pro-inflammatory cell death known as pyroptosis, they do also take part in other cell death processes (NETosis, secondary necrosis, or apoptosis) and exhibit cell-death independent functions depending on the cellular context. Among GSDMs, Gasdermin B (GSDMB) pyroptotic capacity has been a subject of conflicting findings in scientific literature even when its processing, and subsequent activation, by Granzyme A (GZMA) was decoded. Nevertheless, recent groundbreaking publications have shed light on the crucial role of alternative splicing in determining the pyroptotic capacity of GSDMB isoforms, which depends on the presence of exon 6-derived elements. This comprehensive review pays attention to the relevant structural differences among recently crystalized GSDMB isoforms. As a novelty, the structural aspects governing GSDMB isoform susceptibility to GZMA-mediated activation have been investigated. By elucidating the complex roles of GSDMB isoforms, this review aims to deepen the understanding of this multifunctional player and its potential implications in disease pathogenesis and therapeutic interventions. (Figure presented.)., This study was financed by the following grants: Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación (MICINN-AEI, PID2019-104644RB-I00, PDC2022-133252-I00, PID2022-136854OB-I00), the Instituto de Salud Carlos III (CIBERONC, CB16/12/00295), AC21_2/00020 ERA PerMed ERA-NET (cofunded by NextGenerationEU) and the AECC Scientific Foundation (FCAECC PROYE19036MOR and GCTRA18014MATI). DS contract is financed by CIBERONC (partly supported by FEDER funds). SC is funded by the MICINN-AEI PRE2020-095658, Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer

  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • Diaz, Eva
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Alonso-Alconada, Lorena
  • Ferreiros, Alba
  • Abalo, Alicia
  • López Gil, Carlos
  • Oltra, Sara S.
  • de Santiago, Javier
  • Cabrera Díaz, Silvia|||0000-0002-3164-6686
  • Sampayo, Victoria
  • Bouso, Marta
  • Arias, Efigenia
  • Cueva, Juan|||0000-0003-1389-4595
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Vilar, Ana
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Moreno-Bueno, Gema
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
The incidence and mortality of endometrial cancer (EC) have risen in recent years, hence more precise management is needed. Therefore, we combined different types of liquid biopsies to better characterize the genetic landscape of EC in a non-invasive and dynamic manner. Uterine aspirates (UAs) from 60 patients with EC were obtained during surgery and analyzed by next-generation sequencing (NGS). Blood samples, collected at surgery, were used for cell-free DNA (cfDNA) and circulating tumor cell (CTC) analyses. Finally, personalized therapies were tested in patient-derived xenografts (PDXs) generated from the UAs. NGS analyses revealed the presence of genetic alterations in 93% of the tumors. Circulating tumor DNA (ctDNA) was present in 41.2% of cases, mainly in patients with high-risk tumors, thus indicating a clear association with a more aggressive disease. Accordingly, the results obtained during the post-surgery follow-up indicated the presence of ctDNA in three patients with progressive disease. Moreover, 38.9% of patients were positive for CTCs at surgery. Finally, the efficacy of targeted therapies based on the UA-specific mutational landscape was demonstrated in PDX models. Our study indicates the potential clinical applicability of a personalized strategy based on a combination of different liquid biopsies to characterize and monitor tumor evolution, and to identify targeted therapies.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

  • Mota, Alba
  • Oltra, Sara S.
  • Selenica, Pier
  • Moiola, Cristian Pablo|||0000-0001-7218-0184
  • Casas-Arozamena, Carlos|||0000-0002-3279-2482
  • López-Gil, Carlos|||0000-0001-6540-1225
  • Diaz, Eva
  • Gatius, Sonia
  • Ruiz-Miro, María
  • Calvo, Ana|||0000-0002-7953-2629
  • Rojo-Sebastián, Alejandro
  • Hurtado Blanco, P.
  • Piñeiro, Roberto|||0000-0001-9479-139X
  • Colás Ortega, Eva|||0000-0003-0302-4828
  • Gil-Moreno, Antonio|||0000-0003-1106-5590
  • Reis-Filho, Jorge S.|||0000-0003-2969-3173
  • Muinelo-Romay, Laura|||0000-0002-7456-7531
  • Abal Posada, Miguel|||0000-0003-3533-7781
  • Matías-Guiu, Xavier|||0000-0002-7201-6605
  • Weigelt, Britta|||0000-0001-9927-1270
  • Moreno-Bueno, Gema
Analyzing different tumor regions by next generation sequencing allows the assessment of intratumor genetic heterogeneity (ITGH), a phenomenon that has been studied widely in some tumor types but has been less well explored in endometrial carcinoma (EC). In this study, we sought to characterize the spatial and temporal heterogeneity of 9 different ECs using whole-exome sequencing, and by performing targeted sequencing validation of the 42 primary tumor regions and 30 metastatic samples analyzed. In addition, copy number alterations of serous carcinomas were assessed by comparative genomic hybridization arrays. From the somatic mutations, identified by whole-exome sequencing, 532 were validated by targeted sequencing. Based on these data, the phylogenetic tree reconstructed for each case allowed us to establish the tumors' evolution and correlate this to tumor progression, prognosis, and the presence of recurrent disease. Moreover, we studied the genetic landscape of an ambiguous EC and the molecular profile obtained was used to guide the selection of a potential personalized therapy for this patient, which was subsequently validated by preclinical testing in patient-derived xenograft models. Overall, our study reveals the impact of analyzing different tumor regions to decipher the ITGH in ECs, which could help make the best treatment decision.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Gasdermin B over-expression modulates HER2-targeted therapy resistance by inducing protective autophagy through Rab7 activation

  • Gámez-Chiachio, Manuel
  • Molina-Crespo, Ángela
  • Ramos-Nebot, Carmen
  • Martinez-Val, Jeannette
  • Martinez, Lidia
  • Gassner, Katja
  • Llobet, Francisco J.
  • Soriano, Mario
  • Hernandez, Alberto
  • Cordani, Marco
  • Bernadó Morales, Cristina|||0000-0003-1376-0407
  • Diaz, Eva
  • Rojo-Sebastian, Alejandro|||0000-0001-6439-3518
  • Triviño, Juan Carlos
  • Sánchez-García, Laura|||0000-0002-8420-1701
  • Rodríguez-Barrueco, Ruth|||0000-0003-4925-8865
  • Arribas, Joaquín V.|||0000-0002-0504-0664
  • Llobet Navas, David|||0000-0003-1443-7003
  • Sarrió, David
  • Moreno-Bueno, Gema
Gasdermin B (GSDMB) over-expression promotes poor prognosis and aggressive behavior in HER2 breast cancer by increasing resistance to therapy. Decoding the molecular mechanism of GSDMB-mediated drug resistance is crucial to identify novel effective targeted treatments for HER2/GSDMB aggressive tumors. Different in vitro approaches (immunoblot, qRT-PCR, flow cytometry, proteomic analysis, immunoprecipitation, and confocal/electron microscopy) were performed in HER2 breast and gastroesophageal carcinoma cell models. Results were then validated using in vivo preclinical animal models and analyzing human breast and gastric cancer samples. GSDMB up-regulation renders HER2 cancer cells more resistant to anti-HER2 agents by promoting protective autophagy. Accordingly, the combination of lapatinib with the autophagy inhibitor chloroquine increases the therapeutic response of GSDMB-positive cancers in vitro and in zebrafish and mice tumor xenograft in vivo models. Mechanistically, GSDMB N-terminal domain interacts with the key components of the autophagy machinery LC3B and Rab7, facilitating the Rab7 activation during pro-survival autophagy in response to anti-HER2 therapies. Finally, we validated these results in clinical samples where GSDMB/Rab7/LC3B co-expression associates significantly with relapse in HER2 breast and gastric cancers. Our findings uncover for the first time a functional link between GSDMB over-expression and protective autophagy in response to HER2-targeted therapies. GSDMB behaves like an autophagy adaptor and plays a pivotal role in modulating autophagosome maturation through Rab7 activation. Finally, our results provide a new and accessible therapeutic approach for HER2/GSDMB + cancers with adverse clinical outcome. The online version contains supplementary material available at 10.1186/s13046-022-02497-w.